Latest stories on HRMY
Harmony Biosciences (HRMY) Gains Investor Attention with Strong Revenue Growth and Attractive Valuation
GuruFocus64 · neutralgeneral
4 Small-Cap Stocks With Paths to Recovery After the Fed's September Rate Hike
MarketBeat52 · neutralanalyst
Mizuho reiterates Harmony Biosciences stock rating after litigation
Investing.com Analyst Ratings50 · neutralanalyst
Harmony Biosciences drops amid court hearing on Wakix patent
Seeking Alpha38 · neutralgeneral
Centene, Harmony Biosciences lead list of undervalued healthcare stocks
Seeking Alpha64 · neutralanalyst
Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences
Barron's50 · neutralgeneral
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Seeking Alpha64 · neutralanalyst
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
GlobeNewswire50 · neutralgeneral
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Business Insider50 · neutralgeneral
Harmony Biosciences initiated with a Buy at Ladenburg
The Fly63 · neutralanalyst
Harmony Biosciences announces CEO transition and succession
TipRanks48 · neutralgeneral
Harmony Biosciences Holdings, Inc. (HRMY) files 8-K
SEC 8-K50 · neutralgeneral
H.C. Wainwright reiterates Harmony Biosciences stock rating on leadership transition
Investing.com Analyst Ratings50 · neutralanalyst
Why Harmony Biosciences Stock Got Mashed on Monday
The Motley Fool34 · bearishgeneral
Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
PR Newswire58 · neutralproduct/pr
Mizuho positive on Harmony Biosciences CEO transition
The Fly58 · neutralanalyst
Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit
Investors.com34 · bearishgeneral
Why is Harmony Biosciences stock sliding today?
Investing.com Markets38 · neutralgeneral
Harmony Biosciences appoints Peter Anastasiou as CEO
Seeking Alpha52 · neutralgeneral
Harmony Biosciences CEO Jeffrey Dayno to retire, Peter Anastasiou to succeed
The Fly42 · neutralgeneral
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
GlobeNewswire58 · neutralgeneral
Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth
Business Insider58 · neutralgeneral
Harmony Biosciences price target raised to $42 from $39 at Deutsche Bank
The Fly63 · neutralanalyst
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
Business Insider56 · neutralproduct/pr
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
GlobeNewswire56 · neutralproduct/pr